Salubris: The clinical trial application for the self-developed innovative small molecule drug SAL0140 tablets has been accepted

According to the Zhitong Finance APP, Salubris (002294.SZ) announced that it has recently received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0140 tablets (project code: SAL0140) has been accepted.

SAL0140 is an aldosterone synthase inhibitor with independent intellectual property rights, intended to develop indications including uncontrolled hypertension (including resistant hypertension) and chronic kidney disease (CKD). Currently, SAL0140 (uncontrolled hypertension) is in the Phase I clinical stage.

If SAL0140 can be successfully developed and approved for marketing, it is expected to provide targeted new medication options for more patients with hypertension and CKD in specific subfields, meeting unmet clinical needs and further enriching the company's innovative product pipeline in the chronic disease field